Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemlines lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial.
Behind its lead, Stemline is developing a broad portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. In addition, Stemline has built a robust discovery platform called StemScreen which the Company has utilized to identify multiple compounds that target and impair cancer stem cells.
Stemline also possesses a comprehensive intellectual property portfolio that includes the earliest filings in the cancer stem cell field covering cancer stem cell-directed therapeutics, diagnostics, and drug screening.
Prior to founding Stemline, Dr. Bergstein was Medical Director of Access Oncology, Inc. (now Keryx Biopharmaceuticals, Inc. [Nasdaq: KERX]) where he was a key member of the team that in-licensed and developed several clinical stage oncology compounds. Prior to this, he was senior biopharmaceuticals analyst at Cancer Advisors (now Nitron Advisors), a Wall Street-based firm that advises investment funds on public oncology-focused companies. He received a B.A. in mathematics from the University of Pennsylvania, an M.D. from the Mount Sinai Medical Center, and completed an internal medicine residency and hematology-medical oncology fellowship at the New York Presbyterian Hospital-Weill Medical College of Cornell University.
Prior to joining Stemline, Dr. Cirrito was a biopharmaceuticals equities analyst at Piper Jaffray, where he covered large and small cap biotechnology companies. Previously he was a life sciences consultant for A.G. Edwards Capital Partners, a venture capital group . He received a B.A. in Biological Sciences and a Ph.D. in Immunology from Washington University (St. Louis, MO).